Arbutus Biopharma Corporation ABUS Debt-to-equity

Debt-to-equity at other companies

Arrowhead ResearchARWR

0.2×0.0×

Gilead SciencesGILD

2.2×+1.0×

ALN

Alnylam PharmaceuticalsALNY

0.2×-0.9×

AnaptysBio, Inc.ANAB

0×-0.5×

Avalo TherapeuticsAVTX

0×0.0×

Assembly BiosciencesASMB

0×-0.1×

FAQ

What is Arbutus Biopharma Corporation's debt-to-equity?

Arbutus Biopharma Corporation (ABUS) reported debt-to-equity of 0× in Q1 2026.

How has Arbutus Biopharma Corporation's debt-to-equity changed year-over-year?

Arbutus Biopharma Corporation's debt-to-equity decreased by 84.0% year-over-year, from 0× to 0×.

What is the long-term trend for Arbutus Biopharma Corporation's debt-to-equity?

Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's debt-to-equity has grown at a -19.8% compound annual growth rate (CAGR), from 0× to 0×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.